Mangalam Drugs & Organics Limited (MANGALAM) Fair Value & Analysis
Healthcare · IN · Market cap ₹447M
Fair value as of: Jul 3, 2026
From 3 valuation models · updated today
Share price −0.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹23.78 – ₹92.46 · fair‑value band ₹22.64 – ₹33.77 · the ₹28.09 price screens below the ₹28.18 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Mangalam Drugs & Organics Limited (MANGALAM) currently trades at ₹28.09, while our model-based Fair Value estimate is ₹28.18 — implying the stock looks roughly 0.3% undervalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Mangalam Drugs & Organics Limited generated revenue of ₹2.3B at a net margin of -19.1%. Revenue declined 7.5% year over year. It earns a return on equity of -35.2%. Net debt stands at ₹1.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Mangalam Drugs & Organics Limited reported revenue of ₹2.3B in FY2026 versus ₹4.5B in FY2022, a compound −15.1%/yr. Reported net income was −₹444M in FY2026.
Is MANGALAM fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mangalam Drugs & Organics Limited (MANGALAM) undervalued?
What is the fair value of MANGALAM?
What is the quality score of MANGALAM?
What is the revenue of Mangalam Drugs & Organics Limited (MANGALAM)?
What is the net profit margin of MANGALAM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.